Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Inventory (2016 - 2025)

Historic Inventory for Amicus Therapeutics (FOLD) over the last 10 years, with Q3 2025 value amounting to $177.9 million.

  • Amicus Therapeutics' Inventory rose 5426.66% to $177.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.9 million, marking a year-over-year increase of 5426.66%. This contributed to the annual value of $118.8 million for FY2024, which is 9897.82% up from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Inventory is $177.9 million, which was up 5426.66% from $154.9 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Inventory registered a high of $177.9 million during Q3 2025, and its lowest value of $13.3 million during Q3 2022.
  • For the 5-year period, Amicus Therapeutics' Inventory averaged around $63.7 million, with its median value being $51.4 million (2023).
  • Its Inventory has fluctuated over the past 5 years, first crashed by 3986.95% in 2022, then soared by 32899.34% in 2023.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Inventory stood at $26.8 million in 2021, then dropped by 11.19% to $23.8 million in 2022, then skyrocketed by 150.66% to $59.7 million in 2023, then surged by 98.98% to $118.8 million in 2024, then surged by 49.79% to $177.9 million in 2025.
  • Its Inventory stands at $177.9 million for Q3 2025, versus $154.9 million for Q2 2025 and $132.4 million for Q1 2025.